46. Malignant rheumatoid arthritis Clinical trials / Disease details

Clinical trials : 4,325 / Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03618784 (ClinicalTrials.gov)	July 11, 2018	24/7/2018	Safety and Efficacy of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid Arthritis	A Multi-center, Randomized, Double-blind, Parallel, Placebo-controlled Phase I/2a Clinical Trial to Evaluate the Efficacy and Safety of FURESTEM-RA Inj. for Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: FURESTEM-RA Inj;Other: sterile saline	Kang Stem Biotech Co., Ltd.	NULL	Recruiting	19 Years	80 Years	All	33	Phase 1/Phase 2	Korea, Republic of
2	NCT03106259 (ClinicalTrials.gov)	June 29, 2016	3/4/2017	Long-term Observational Study to Evaluation the Safety of FURESTEM-RA Inj	Observational Study to Evaluate the Safety of FURESTEM-RA Inj. in Moderate to Severe Rheumatoid Arthritis Patients Who Participated in Phase 1 Clinical Trial of FURESTEM-RA Inj	Rheumatoid Arthritis	Drug: FURESTEM-RA Inj.	Kang Stem Biotech Co., Ltd.	NULL	Active, not recruiting	19 Years	80 Years	All	9	Phase 1	Korea, Republic of
3	NCT02221258 (ClinicalTrials.gov)	October 2014	18/8/2014	Safety of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid Arthritis(RA)	Phase 1 Clinical Trial to Evaluate the Safety of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: FURESTEM-RA Inj.	Kang Stem Biotech Co., Ltd.	NULL	Completed	19 Years	80 Years	Both	9	Phase 1	Korea, Republic of